Indanes-Properties, Preparation, and Presence in Ligands for G Protein Coupled Receptors

Medicinal Research Reviews

Volumn 35, Issue 6, 2015, Pages 1097-1126

  Vilums, Maris ^a   Heuberger, Jules ^a   Heitman, Laura H ^a   Ijzerman, Adriaan P ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Drug discovery; G protein coupled receptor; Indane; Privileged structure

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR 2; CHEMOKINE RECEPTOR CCR2; DOPAMINE RECEPTOR; ENDOTHELIN RECEPTOR; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 119; G PROTEIN COUPLED RECEPTOR 40; GHRELIN RECEPTOR; INDAN DERIVATIVE; INDANONE DERIVATIVE; MELANIN CONCENTRATING HORMONE RECEPTOR; MELATONIN RECEPTOR; METABOTROPIC RECEPTOR; NATURAL PRODUCT; PROSTAGLANDIN F; PROTEINASE ACTIVATED RECEPTOR 2; SEROTONIN RECEPTOR; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 2; LIGAND;

ARTICLE; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; INFLAMMATORY DISEASE; MEDICINAL CHEMISTRY; METABOLIC DISORDER; MOLECULARLY TARGETED THERAPY; NONHUMAN; PHYSICAL CHEMISTRY; STRUCTURE ACTIVITY RELATION; CHEMISTRY; DRUG DEVELOPMENT; SYNTHESIS;

DRUG DISCOVERY; INDANS; LIGANDS; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84943541669     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.21352     Document Type: Article

References (114)

1. Robinson FA, Suthers AJ, Walker TK. Some new antiseptics related to indan-1:3-dione. Biochem J 1932;26(6):1890-1901.
2. Bardouille V, Mootoo BS, Hirotsu K, Clardy J. Sesquiterpenes from Pityrogramma calomelanos. Phytochemistry 1978;17(2):275-277.
3. Li C, Roege KE, Kelly WL. Analysis of the indanomycin biosynthetic gene cluster from Streptomyces antibioticus NRRL 8167. ChemBioChem 2009;10(6):1064-1072.
4. Miao SC, Anstee MR, Baichwal V, Park A. Stawamycin, a new pyrroloketoindane natural product from the cultures of Streptomyces sp. Tetrahedron Lett 1995;36(32):5699-5702.
5. Dorsey BD, Levin RB, Mcdaniel SL, Vacca JP, Guare JP, Darke PL, Zugay JA, Emini EA, Schleif WA, Quintero JC, Lin JH, Chen IW, Holloway MK, Fitzgerald PMD, Axel MG, Ostovic D, Anderson PS, Huff JR. L-735524-The design of a potent and orally bioavailable Hiv protease inhibitor. J Med Chem 1994;37(21):3443-3451.
6. Villetti G, Bregola G, Bassani F, Bergamaschi M, Rondelli I, Pietra C, Simonato M. Preclinical evaluation of CHF3381 as a novel antiepileptic agent. Neuropharmacology 2001;40(7):866-878.
7. Yu H, Kim IJ, Folk JE, Tian X, Rothman RB, Baumann MH, Dersch CM, Flippen-Anderson JL, Parrish D, Jacobson AE, Rice KC. Synthesis and pharmacological evaluation of 3-(3, 4-dichlorophenyl)-1-indanamine derivatives as nonselective ligands for biogenic amine transporters. J Med Chem 2004;47(10):2624-2634.
8. Juby PF, Partyka RA, Hudyma TW. 1-Indancarboxylic acids and derivatives. Patent US3565943, 1971.
9. Nestico PF, Morganroth J, Horowitz LN, Mulhern C. Efficacy of oral and intravenous indecainide in ventricular arrhythmias. Am J Cardiol 1987;59(15):1332-1336.
10. Woltersdorf OW, Jr., deSolms SJ, Stokker GE, Cragoe EJ, Jr. (Acylaryloxy)acetic acid diuretics. 5. [(2-Alkyl- and 2, 2-disubstituted-1, 3-dioxo-5-indanyl)oxy]acetic acids. J Med Chem 1984;27(7):840-845.
11. Fisher MM, Wilensky ND, Griffith RW, Drumm A, Diefenbach AE, Frankel GJ. Hedulin (phenindione), a new anticoagulant; a comparison of the anticoagulant action of Hedulin and combinations of Hedulin and Dicumarol. N Y State J Med 1954;54(6):778-783.
12. Syrchina AI, Semenov AA. Natural Indanones. Khimiya Prirodnykh Soedinenii 1982(1):3-14.
13. Chen YH, Chang FR, Lu MC, Hsieh PW, Wu MJ, Du YC, Wu YC. New benzoyl glucosides and cytotoxic pterosin sesquiterpenes from Pteris ensiformis burm. Molecules 2008;13(2):255-266.
14. Hsu FL, Huang CF, Chen YW, Yen YP, Wu CT, Uang BJ, Yang RS, Liu SH. Antidiabetic effects of pterosin A, a small-molecular-weight natural product, on diabetic mouse models. Diabetes 2013;62(2):628-638.
15. Ho ST, Yang MS, Wu TS, Wang CH. Studies on the Taiwan Folk Medicine .3. A smooth-muscle relaxant from Onychium siliculosum, Onitin. Planta Med 1985;51(2):148-150.
16. Sheridan H, Frankish N, Farrell R. Smooth muscle relaxant activity of pterosin Z and related compounds. Planta Med 1999;65(3):271-272.
17. Ito T, Tanaka T, Iinuma M, Nakaya K, Takahashi Y, Sawa R, Murata J, Darnaedi D. Three new resveratrol oligomers from the stem bark of Vatica pauciflora. J Nat Prod 2004;67(6):932-937.
18. Kopp P. Resveratrol, a phytoestrogen found in red wine. A possible explanation for the conundrum of the 'French paradox'? Eur J Endocrinol 1998;138(6):619-620.
19. Okpekon T, Millot M, Champy P, Gleye C, Yolou S, Bories C, Loiseau P, Laurens A, Hocquemiller R. A novel 1-indanone isolated from Uvaria afzelii roots. Nat Prod Res 2009;23(10):909-915.
20. Donnelly DMX, O'Reilly J, Polonsky J, van Eijk GW. Fomajorin S and D from fomes annosus (FR) cooke. Tetrahedron Lett 1982;23(51):5451-5452.
21. Kim SH, Kwon SH, Park SH, Lee JK, Bang HS, Nam SJ, Kwon HC, Shin J, Oh DC. Tripartin, a histone demethylase inhibitor from a bacterium associated with a dung beetle larva. Org Lett 2013;15(8):1834-1837.
22. Wislicenus W. Einwirkung von Essigester auf Phtalsäureester. Justus Liebigs Ann Chem 1888;246(3):347-355.
23. Gabriel S, Hausmann J. Einwirkung des o-Cyanbenzylchlorids auf Natracetessigester. Ber Dtsch Chem Ges 1889;22(2):2017-2019.
24. Kramer G, Spilker A. Ueber das Inden und Styrol im Steinkohlentheer. Ber Dtsch Chem Ges 1890;23(2):3276-3283.
25. Miyaura N, Ishiyama T, Sasaki H, Ishikawa M, Satoh M, Suzuki A. Palladium-catalyzed intermolecular and intramolecular cross-coupling reactions of B-alkyl-9-borabicyclo[3.3.1]nonane derivatives with 1-halo-1-alkenes or haloarenes-Syntheses of functionalized alkenes, arenes, and cycloalkenes via a hydroboration coupling sequence. J Am Chem Soc 1989;111(1):314-321.
26. Katritzky AR, Wang XJ, Xie LH, Toader D. Functionalized (benzotriazol-1-yl)methanes as 1, 1-dipole synthon equivalents in diverse annulations to aromatic and heteroaromatic rings. J Org Chem 1998;63(10):3445-3449.
27. Maux Le P, Srour HF, Simonneaux G. Enantioselective water-soluble iron-porphyrin-catalyzed epoxidation with aqueous hydrogen peroxide and hydroxylation with iodobenzene diacetate. Tetrahedron 2012;68(29):5824-5828.
28. Nishioka Y, Uchida T, Katsuki T. Enantio- and regioselective intermolecular benzylic and allylic C-H bond amination. Angew Chem Int Ed 2013;52(6):1739-1742.
29. Bailey WF, Longstaff SC. Generation and cyclization of a benzyne-tethered alkyllithium: Preparation of 4-substituted indans. J Org Chem 1998;63(3):432-433.
30. George P, Hall D, Hartung R, Kosley RW, Scotese AC. Substituted para-biphenyloxymethyl dihydro oxazolopyrimidinones, preparation and use thereof. Patent WO2011034828, 2011.
31. Hartmann RW, Bayer H, Grun G. Aromatase inhibitors-Syntheses and structure-activity studies of novel pyridyl-substituted indanones, indans, and tetralins. J Med Chem 1994;37(9):1275-1281.
32. Mathison IW, Solomons WE, Jones RH. Synthesis of cyclopentano-1, 2, 3, 4-tetrahydroisoquinolines-Novel heterocyclic-systems. J Org Chem 1974;39(19):2852-2855.
33. Meneguzzo E, Norcini G, Bassi GL. Process for the preparation of aromatic alpha-hydroxy ketones. Patent WO2009135895, 2009.
34. Kangani CO, Day BW. Mild, efficient Friedel-Crafts acylations from carboxylic acids using cyanuric chloride and AlCl3. Org Lett 2008;10(13):2645-2648.
35. Wang CD, Hsieh YF, Liu RS. Gold-catalyzed carboalkoxylations of 2-ethynylbenzyl ethers to form 1- and 2-indanones chemoselectively: Effects of ligands and solvents. Adv Synth Catal 2014;356(1):144-152.
36. Azemi T, Kitamura M, Narasaka K. Transformation of 1, 5-and 1, 6-dienes to carbocycles by hydrozirconation and oxidation with cerium(IV) compounds. Tetrahedron 2004;60(6):1339-1344.
37. Vilums M, Zweemer AJM, Barmare F, Gracht AMF, Bleeker DCT, Yu Z, Vries H, Gross R, Clemens J, Krenitsky P, Brussee J, Stamos D, Saunders J, Heitman LH, Ijzerman AP. When structure-affinity relationships meet structure-kinetics relationships: 3-((Inden-1-yl)amino)-1-isopropyl-cyclopentane-1-carboxamides as CCR2 antagonists. Eur J Med Chem 2015;93:121-134.
38. Garland SL. Are GPCRs still a source of new targets? J Biomol Screen 2013;18(9):947-966.
39. LeWitt PA, Hauser RA, Lu M, Nicholas AP, Weiner W, Coppard N, Leinonen M, Savola JM. Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study). Neurology 2012;79(2):163-169.
40. Savola JM, Hill M, Engstrom M, Merivuori H, Wurster S, McGuire SG, Fox SH, Crossman AR, Brotchie JM. Fipamezole (JP-1730) is a potent alpha(2) adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Mov Disord 2003;18(8):872-883.
41. Cordi AA, Berque-Bestel I, Persigand T, Lacoste JM, Newman-Tancredi A, Audinot V, Millan MJ. Potential antidepressants displayed combined alpha(2)-adrenoceptor antagonist and monoamine uptake inhibitor properties. J Med Chem 2001;44(5):787-805.
42. Karjalainen A, Huhtala P, Savola JM, Wurster S, Eloranta M, Hillila M, Saxlund R, Cockcroft V, Karjalainen A. Imidazole derivatives having affinity for alpha2 receptors. Patent US20020007074, 2001.
43. RecroPharma Pipeline. Available at: http://recropharma.com/?page_id=95.
44. Lehtimaki J, Leino T, Koivisto A, Viitamaa T, Lehtimaki T, Haapalinna A, Kuokkanen K, Virtanen R. In vitro and in vivo profiling of fadolmidine, a novel potent alpha(2)-adrenoceptor agonist with local mode of action. Eur J Pharmacol 2008;599(1-3):65-71.
45. Hacksell U, Arvidsson LE, Svensson U, Nilsson JLG, Wikstrom H, Lindberg P, Sanchez D, Hjorth S, Carlsson A, Paalzow L. Monophenolic 2-(dipropylamino)indans and related-compounds-Central dopamine-receptor stimulating activity. J Med Chem 1981;24(4):429-434.
46. Arneric SP, Long JP, Williams M, Goodale DB, Mott J, Lakoski JM, Gebhart GF. Rds-127 (2-di-normal-propylamino-4, 7-dimethoxyindane)-Central effects of a new dopamine receptor agonist. J Pharmacol Exp Ther 1983;224(1):161-170.
47. Cannon JG, Perez JA, Bhatnagar RK, Long JP, Sharabi FM. Conformationally restricted congeners of dopamine derived from 2-aminoindan. J Med Chem 1982;25(12):1442-1446.
48. Waters N, Svensson K, Haadsma-Svensson SR, Smith MW, Carlsson A. The dopamine D3-receptor: A postsynaptic receptor inhibitory on rat locomotor activity. J Neural Transm Gen Sect 1993;94(1):11-19.
49. Bogeso KP. Neuroleptic activity and dopamine-uptake inhibition in 1-piperazino-3-phenylindans. J Med Chem 1983;26(7):935-947.
50. Svendsen O, Arnt J, Boeck V, Bogeso KP, Christensen AV, Hyttel J, Larsen JJ. The neuropharmacological profile of tefludazine, a potential antipsychotic drug with dopamine and serotonin receptor antagonistic effects. Drug Dev Res 1986;7(1):35-47.
51. Bogeso KP, Arnt J, Frederiksen K, Hansen HO, Hyttel J, Pedersen H. Enhanced D-1 affinity in a series of piperazine ring-substituted 1-piperazino-3-arylindans with potential atypical antipsychotic activity. J Med Chem 1995;38(22):4380-4392.
52. Millan MJ, Rivet JM, Canton H, Lejeune F, Gobert A, Widdowson P, Bervoets K, Brocco M, Peglion JL. S-15535-A highly selective benzodioxopiperazine 5-Ht1a receptor ligand which acts as an agonist and an antagonist at presynaptic and postsynaptic sites respectively. Eur J Pharmacol 1993;230(1):99-102.
53. Peglion JL, Goument B, Despaux N, Charlot V, Giraud H, Nisole C, Newman-Tancredi A, Dekeyne A, Bertrand M, Genissel P, Millan MJ. Improvement in the selectivity and metabolic stability of the serotonin 5-HT(1A) ligand, S 15535: A series of cis- and trans-2-(arylcycloalkylamine) 1-indanols. J Med Chem 2002;45(1):165-176.
54. Hatanaka K, Nomura T, Hidaka K, Takeuchi H, Yatsugi S, Fujii M, Yamaguchi T. Biochemical profile of YM992, a novel selective serotonin reuptake inhibitor with 5-HT2A receptor antagonistic activity. Neuropharmacology 1996;35(11):1621-1626.
55. McLean TH, Chambers JJ, Parrish JC, Braden MR, Marona-Lewicka D, Kurrasch-Orbaugh D, Nichols DE. C-(4, 5, 6-trimethoxyindan-1-yl)methanamine: A mescaline analogue designed using a homology model of the 5-HT2A receptor. J Med Chem 2006;49(25):7558-7558.
56. Mesquida N, Lopez-Perez S, Dinares I, Frigola J, Merce R, Holenz J, Perez R, Burgueno J, Alcalde E. Identification of novel indanylsulfonamide guanylhydrazones as potent 5-HT6 serotonin receptor antagonists. J Med Chem 2009;52(19):6153-6157.
57. Kloubert S, Mathe-Allainmat M, Andrieux J, Sicsic S, Langlois M. Synthesis of benzocycloalkane derivatives as new conformationally restricted ligands for melatonin receptors. Bioorg Med Chem Lett 1998;8(23):3325-3330.
58. Drijfhout WJ, de Vries JB, Homan EJ, Brons HF, Copinga S, Gruppen G, Beresford IJM, Hagan RM, Grol CJ, Westerink BHC. Novel non-indolic melatonin receptor agonists differentially entrain endogenous melatonin rhythm and increase its amplitude. Eur J Pharmacol 1999;382(3):157-166.
59. Jansen JM, Copinga S, Gruppen G, Molinari EJ, Dubocovich ML, Grol CJ. The high affinity melatonin binding site probed with conformationally restricted ligands. 1. Pharmacophore and minireceptor models. Biorg Med Chem 1996;4(8):1321-1332.
60. Mattson RJ, Catt JD, Keavy D, Sloan CP, Epperson J, Gao Q, Hodges DB, Iben L, Mahle CD, Ryan E, Yocca FD. Indanyl piperazines as melatonergic MT2 selective agents. Bioorg Med Chem Lett 2003;13(6):1199-1202.
61. Fukatsu K, Uchikawa O, Kawada M, Yamano T, Yamashita M, Kato K, Hirai K, Hinuma S, Miyamoto M, Ohkawa S. Synthesis of a novel series of benzocycloalkene derivatives as melatonin receptor agonists. J Med Chem 2002;45(19):4212-4221.
62. Uchikawa O, Fukatsu K, Tokunoh R, Kawada M, Matsumoto K, Imai Y, Hinuma S, Kato K, Nishikawa H, Hirai K, Miyamoto M, Ohkawa S. Synthesis of a novel series of tricyclic indan derivatives as melatonin receptor agonists. J Med Chem 2002;45(19):4222-4239.
63. Pellegrini-Giampietro DE, Cozzi A, Peruginelli F, Leonardi P, Meli E, Pellicciari R, Moroni F. 1-Aminoindan-1, 5-dicarboxylic acid and (S)-(+)-2-(3'-carboxybicyclo[1.1.1] pentyl)-glycine, two mGlu1 receptor-preferring antagonists, reduce neuronal death in in vitro and in vivo models of cerebral ischaemia. Eur J Neurosci 1999;11(10):3637-3647.
64. Pellicciari R, Luneia R, Costantino G, Marinozzi M, Natalini B, Jakobsen P, Kanstrup A, Lombardi G, Moroni F, Thomsen C. 1-Aminoindan-1, 5-dicarboxylic acid-A novel antagonist at phospholipase C-linked metabotropic glutamate receptors. J Med Chem 1995;38(19):3717-3719.
65. Conn PJ, Jones CK. Promise of mGluR2/3 activators in psychiatry. Neuropsychopharmacology 2009;34(1):248-249.
66. Bonnefous C, Vernier JM, Hutchinson JH, Gardner MF, Cramer M, James JK, Rowe BA, Daggett LP, Schaffhauser H, Kamenecka TM. Biphenyl-indanones: Allosteric potentiators of the metabotropic glutamate subtype 2 receptor. Bioorg Med Chem Lett 2005;15(19):4354-4358.
67. Harmar AJ, Marston HM, Shen SB, Spratt C, West KM, Sheward WJ, Morrison CF, Dorin JR, Piggins HD, Reubi JC, Kelly JS, Maywood ES, Hastings MH. The VPAC(2) receptor is essential for circadian function in the mouse suprachiasmatic nuclei. Cell 2002;109(4):497-508.
68. Goetzl EJ, Voice JK, Shen SB, Dorsam G, Kong Y, West KM, Morrison CF, Harmar AJ. Enhanced delayed-type hypersensitivity and diminished immediate-type hypersensitivity in mice lacking the inducible VPAC(2) receptor for vasoactive intestinal peptide. Proc Natl Acad Sci USA 2001;98(24):13854-13859.
69. Levinson DF, Duan JB, Oh S, Wang K, Sanders AR, Shi JX, Zhang N, Mowry BJ, Olincy A, Amin F, Cloninger CR, Silverman JM, Buccola NG, Byerley WF, Black DW, Kendler KS, Freedman R, Dudbridge F, Pe'er I, Hakonarson H, Bergen SE, Fanous AH, Holmans PA, Gejman PV. Copy number variants in schizophrenia: Confirmation of five previous findings and new evidence for 3q29 microdeletions and VIPR2 duplications. Am J Psychiatry 2011;168(3):302-316.
70. Vacic V, McCarthy S, Malhotra D, Murray F, Chou HH, Peoples A, Makarov V, Yoon S, Bhandari A, Corominas R, Iakoucheva LM, Krastoshevsky O, Krause V, Larach-Walters V, Welsh DK, Craig D, Kelsoe JR, Gershon ES, Leal SM, Aquila MD, Morris DW, Gill M, Corvin A, Insel PA, McClellan J, King MC, Karayiorgou M, Levy DL, DeLisi LE, Sebat J. Duplications of the neuropeptide receptor gene VIPR2 confer significant risk for schizophrenia. Nature 2011;471(7339):499-503.
71. Asnicar MA, Koster A, Heiman ML, Tinsley F, Smith DP, Galbreath E, Fox N, Ma YL, Blum WF, Hsiung HM. Vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating peptide receptor 2 deficiency in mice results in growth retardation and increased basal metabolic rate. Endocrinology 2002;143(10):3994-4006.
72. Chu A, Caldwell JS, Chen YA. Identification and characterization of a small molecule antagonist of human VPAC(2) receptor. Mol Pharmacol 2010;77(1):95-101.
73. Odonnell SR, Wanstall JC. Evidence that ICI 118, 551 is a potent, highly beta2-selective adrenoceptor antagonist and can be used to characterize beta-adrenoceptor populations in tissues. Life Sci 1980;27(8):671-677.
74. Baur F, Beattie D, Beer D, Bentley D, Bradley M, Bruce I, Charlton SJ, Cuenoud B, Ernst R, Fairhurst RA, Faller B, Farr D, Keller T, Fozard JR, Fullerton J, Garman S, Hatto J, Hayden C, He HD, Howes C, Janus D, Jiang ZJ, Lewis C, Loeuillet-Ritzler F, Moser H, Reilly J, Steward A, Sykes D, Tedaldi L, Trifilieff A, Tweed M, Watson S, Wissler E, Wyss D. The identification of indacaterol as an ultralong-acting inhaled beta(2)-adrenoceptor agonist. J Med Chem 2010;53(9):3675-3684.
75. Beattie D, Beer D, Bradley ME, Bruce I, Charlton SJ, Cuenoud BM, Fairhurst RA, Farr D, Fozard JR, Janus D, Rosethorne EM, Sandham DA, Sykes DA, Trifilieff A, Turner KL, Wissler E. An investigation into the structure-activity relationships associated with the systematic modification of the beta(2)-adrenoceptor agonist indacaterol. Bioorg Med Chem Lett 2012;22(19):6280-6285.
76. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006;354(6):610-621.
77. Serbina NV, Pamer EG. Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2. Nat Immunol 2006;7(3):311-317.
78. Dawson TC, Kuziel WA, Osahar TA, Maeda N. Absence of CC chemokine receptor-2 reduces atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis 1999;143(1):205-211.
79. Kim YK, Oh HB, Lee EY, Gho YS, Lee JE, Kim YY. Association between a genetic variation of CC chemokine receptor-2 and atopic asthma. Allergy 2007;62(2):208-209.
80. Fife BT, Huffnagle GB, Kuziel WA, Karpus WJ. CC chemokine receptor 2 is critical for induction of experimental autoimmune encephalomyelitis. J Exp Med 2000;192(6):899-905.
81. Ogata H, Takeya M, Yoshimura T, Takagi K, Takahashi K. The role of monocyte chemoattractant protein-1 (MCP-1) in the pathogenesis of collagen-induced arthritis in rats. J Pathol 1997;182(1):106-114.
82. White FA, Feldman P, Miller RJ. Chemokine signaling and the management of neuropathic pain. Mol Interventions 2009;9(4):188-195.
83. Vilums M, Zweemer AJ, Yu Z, de Vries H, Hillger JM, Wapenaar H, Bollen IA, Barmare F, Gross R, Clemens J, Krenitsky P, Brussee J, Stamos D, Saunders J, Heitman LH, Ijzerman AP. Structure-kinetic relationships-An overlooked parameter in hit-to-lead optimization: A case of cyclopentylamines as chemokine receptor 2 antagonists. J Med Chem 2013;56(19):7706-7714.
84. Budzik BW, Bury MJ, Gu M, Liu R, Ren F, Sehon CA, Wang GZ, Zhang J. Spiroindenes and spiroindanes as modulators of chemokine receptors. Patent WO2009023754, 2009.
85. Budzik BW, Haile PA, Hughes TV, Sehon CA, Wang GZ. Spirodihydrobenzofurans as modulators of chemokine receptors. Patent WO2009061881, 2009.
86. Steinhoff M, Buddenkotte J, Shpacovitch V, Rattenholl A, Moormann C, Vergnolle N, Luger TA, Hollenberg MD. Proteinase-activated receptors: Transducers of proteinase-mediated signaling in inflammation and immune response. Endocr Rev 2005;26(1):1-43.
87. Ossovskaya VS, Bunnett NW. Protease-activated receptors: Contribution to physiology and disease. Physiol Rev 2004;84(2):579-621.
88. Barry GD, Suen JY, Le GT, Cotterell A, Reid RC, Fairlie DP. Novel agonists and antagonists for human protease activated receptor 2. J Med Chem 2010;53(20):7428-7440.
89. Weber MA, Black H, Bakris G, Krum H, Linas S, Weiss R, Linseman JV, Wiens BL, Warren MS, Lindholm LH. A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: A randomised, double-blind, placebo-controlled trial. Lancet 2009;374(9699):1423-1431.
90. Cristol JP, Warner TD, Thiemermann C, Vane JR. Mediation via different receptors of the vasoconstrictor effects of endothelins and sarafotoxins in the systemic circulation and renal vasculature of the anesthetized rat. Brit J Pharmacol 1993;108(3):776-779.
91. Elliott JD, Lago MA, Cousins RD, Gao AM, Leber JD, Erhard KF, Nambi P, Elshourbagy NA, Kumar C, Lee JA, Bean JW, Debrosse CW, Eggleston DS, Brooks DP, Feuerstein G, Ruffolo RR, Weinstock J, Gleason JG, Peishoff CE, Ohlstein EH. 1, 3-Diarylindan-2-carboxylic acids, potent and selective nonpeptide endothelin receptor antagonists. J Med Chem 1994;37(11):1553-1557.
92. Ohlstein EH, Nambi P, Lago A, Hay DWP, Beck G, Fong KL, Eddy EP, Smith P, Ellens H, Elliott JD. Nonpeptide endothelin receptor antagonists. 6. Pharmacological characterization of SE 217242, a potent and highly bioavailable endothelin receptor antagonist. J Pharmacol Exp Ther 1996;276(2):609-615.
93. Bogeso KP, Arnt J, Boeck V, Christensen AV, Hyttel J, Jensen KG. Antihypertensive activity in a series of 1-piperazino-3-phenylindans with potent 5-HT2-antagonistic activity. J Med Chem 1988;31(12):2247-2256.
94. Kowalski TJ, McBriar MD. Therapeutic potential of melanin-concentrating hormone-1 receptor antagonists for obesity the treatment of obesity. Expert Opin Investig Drugs 2004;13(9):1113-1122.
95. Handlon AL, Zhou HQ. Melanin-concentrating hormone-1 receptor antagonists for the treatment of obesity. J Med Chem 2006;49(14):4017-4022.
96. Erickson SD, Banner B, Berthel S, Conde-Knape K, Falcioni F, Hakimi I, Hennessy B, Kester RF, Kim K, Ma C, McComas W, Mennona F, Mischke S, Orzechowski L, Qian Y, Salari H, Tengi J, Thakkar K, Taub R, Tilley JW, Wang H. Potent, selective MCH-1 receptor antagonists. Bioorg Med Chem Lett 2008;18(4):1402-1406.
97. Qian YM, Conde-Knape K, Erickson SD, Falcioni F, Gillespie P, Hakimi I, Mennona F, Ren YL, Salari H, So SS, Tilley JW. Potent MCH-1 receptor antagonists from cis-1, 4-diaminocyclohexane-derived indane analogs. Bioorg Med Chem Lett 2013;23(14):4216-4220.
98. Sakairi M, Kogami M, Torii M, Kataoka H, Fujieda H, Makino M, Kataoka D, Okamoto R, Miyazawa T, Okabe M, Inoue M, Takahashi N, Harada S, Watanabe N. Synthesis and SAR studies of bicyclic amine series GPR119 agonists. Bioorg Med Chem Lett 2012;22(15):5123-5128.
99. Itoh Y, Kawamata Y, Harada M, Kobayashi M, Fujii R, Fukusumi S, Ogi K, Hosoya M, Tanaka Y, Uejima H, Tanaka H, Maruyama M, Satoh R, Okubo S, Kizawa H, Komatsu H, Matsumura F, Noguchi Y, Shinobara T, Hinuma S, Fujisawa Y, Fujino M. Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature 2003;422(6928):173-176.
100. Takeda. Available at: http://www.takeda.com/news/2013/20131227_6117.html.
101. Himmelsbach F, Eckhardt M, Langkopf E, Peters S. New indanyloxydihydrobenzofuranylacetic acids Patent US20130289074A1, 2013.
102. Kaku K. Fasiglifam as a new potential treatment option for patients with type 2 diabetes. Expert Opin Pharmacother 2013;14(18):2591-2600.
103. Dezaki K, Sone H, Koizumi M, Nakata M, Kakei M, Nagai H, Hosoda H, Kangawa K, Yada T. Blockade of pancreatic islet-derived ghrelin enhances insulin secretion to prevent high-fat diet-induced glucose intolerance. Diabetes 2006;55(12):3486-3493.
104. Bhattacharya SK, Cameron KOK, Fernando DP, Kung DW-S, Londregan AT, McClure KF, Simila STM. 2, 3-Dihydro-1H-inden-1-yl-2, 7-diazaspiro[3.6]nonane derivatives and their use as antagonists or inverse agonists of the ghrelin receptor. Patent WO2011114271A1, 2011.
105. Brune ME, O'Neill AB, Gauvin DM, Katwala SP, Altenbach RJ, Brioni JD, Hancock AA, Sullivan JP. Comparison of alpha 1-adrenoceptor agonists in canine urethral pressure profilometry and abdominal leak point pressure models. J Urol 2001;166(4):1555-1559.
106. Whitlock GA, Conlon K, McMurray G, Roberts LR, Stobie A, Thurlow RJ. Novel 2-imidazoles as potent and selective alpha(1A) adrenoceptor partial agonists. Bioorg Med Chem Lett 2008;18(9):2930-2934.
107. Conlon K, Christy C, Westbrook S, Whitlock G, Roberts L, Stobie A, McMurray G. Pharmacological properties of 2-((R-5-chloro-4-methoxymethylindan-1-yl)-1H-imidazole (PF-3774076), a novel and selective alpha 1(A)-adrenergic partial agonist, in in vitro and in vivo models of urethral function. J Pharmacol Exp Ther 2009;330(3):892-901.
108. Roberts LR, Bryans J, Conlon K, McMurray G, Stobie A, Whitlock GA. Novel 2-imidazoles as potent, selective and CNS penetrant alpha(1A) adrenoceptor partial agonists. Bioorg Med Chem Lett 2008;18(24):6437-6440.
109. Makino S, Zaragoza DB, Mitchell BF, Robertson S, Olson DM. Prostaglandin F-2 alpha and its receptor as activators of human decidua. Semin Reprod Med 2007;25(1):60-68.
110. Lee PY, Shao H, Xu L, Qu CK. The Effect of prostaglandin-F2-alpha on intraocular-pressure in normotensive human-subjects. Invest Ophthalmol Vis Sci 1988;29(10):1474-1477.
111. Lai J, Jin H, Yang R, Winer J, Li W, Yen R, King KL, Zeigler F, Ko A, Cheng J, Bunting S, Paoni NF. Prostaglandin F2 alpha induces cardiac myocyte hypertrophy in vitro and cardiac growth in vivo. Am J Physiol 1996;271(6 Pt 2):H2197-H2208.
112. Bryer MD, Breyer RM. G protein-coupled prostanoid receptors and the kidney. Annu Rev Physiol 2001;63:579-605.
113. Griffin BW, Klimko P, Crider JY, Sharif NA. AL-8810: A novel prostaglandin F-2 alpha analog with selective antagonist effects at the prostaglandin F-2 alpha (FP) receptor. J Pharmacol Exp Ther 1999;290(3):1278-1284.
114. Liang YB, Li C, Guzman VM, Chang WW, Evinger AJ, Pablo JV, Woodward DF. Upregulation of orphan nuclear receptor Nur77 following PGF(2 alpha), Bimatoprost, and Butaprost treatments. Essential role of a protein kinase C pathway involved in EP2 receptor activated Nur77 gene transcription. Br J Pharmacol 2004;142(4):737-748.